AbbVie Inc. ABBV reported second-quarter 2025 adjusted EPS of $2.97, which beat the Zacks Consensus Estimate of $2.89. The reported figure also exceeded the company’s guidance of $2.84-$2.88 issued ...
AbbVie Inc. ABBV reported third-quarter 2025 adjusted EPS of $1.86, which beat the Zacks Consensus Estimate of $1.77. The reported figure also exceeded the company’s guidance of $1.74-$1.78 issued ...
AbbVie ABBV has built a substantial neuroscience franchise. While the segment was initially anchored by Botox Therapeutic and the depression drug Vraylar, its offerings now include the oral migraine ...
AbbVie ABBV holds a leadership position in the neuroscience space, which encompasses blockbuster medications such as Botox Therapeutic and depression drug Vraylar. Over the years, the company has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results